311 related articles for article (PubMed ID: 36336488)
1. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
2. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
3. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
Villain N
Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
[TBL] [Abstract][Full Text] [Related]
5. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
6. Passive Immunotherapies Targeting Amyloid-
Marković M; Milošević J; Wang W; Cao Y
Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A; Blanc F; Collongues N
Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
[TBL] [Abstract][Full Text] [Related]
8. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
9. Passive Alzheimer's immunotherapy: A promising or uncertain option?
Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B
Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156
[TBL] [Abstract][Full Text] [Related]
10. How donanemab data address the coverage with evidence development questions.
Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
[TBL] [Abstract][Full Text] [Related]
11. [Causal treatment of Alzheimer's disease: amyloid antibodies].
Pawlowski M; Warnecke T
Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
[TBL] [Abstract][Full Text] [Related]
12. Vascular Considerations for Amyloid Immunotherapy.
Foley KE; Wilcock DM
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):709-719. PubMed ID: 36269539
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?].
Villain N
Geriatr Psychol Neuropsychiatr Vieil; 2022 Jun; 20(2):256-260. PubMed ID: 35929392
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
15. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
[TBL] [Abstract][Full Text] [Related]
16. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
Park KW
Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
18. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapies in Alzheimer's disease: state of the art and potential use in the elderly].
Delrieu J; Ousset PJ
Geriatr Psychol Neuropsychiatr Vieil; 2023 Jun; 21(2):233-240. PubMed ID: 37519082
[TBL] [Abstract][Full Text] [Related]
20. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]